All In Biotech

FDA programs

Orphan drug designation: what it means and how to find orphan drugs

Orphan drug designation explained: the under-200,000 rule, 7 years of exclusivity, tax credit and fee waiver, and where to look up orphan drugs and approvals.

By the All In Biotech editorial team · Published November 18, 2026 · 6 min read

Orphan drug designation is a status FDA grants to a drug or biologic intended to treat, diagnose or prevent a rare disease, defined in US law as one affecting fewer than 200,000 people in the United States. Designation brings incentives, including seven years of market exclusivity after approval, a tax credit on clinical trial costs and an exemption from FDA application fees. It does not mean the drug is approved or that the approval bar is lower.

Where orphan designation comes from

The Orphan Drug Act was signed in January 1983. Before it, companies had little reason to develop treatments for small patient groups because sales would rarely cover the cost of trials. The Act set up financial incentives to change that calculation.

A 1984 amendment added the numerical definition used today. FDA's rules for the program are in 21 CFR Part 316, and the program is run by FDA's Office of Orphan Products Development (OOPD).

Who qualifies

A drug can receive orphan designation in one of two ways:

  1. Prevalence: the disease or condition affects fewer than 200,000 people in the United States. For vaccines, diagnostics and preventive drugs, the test is the number of people who would receive the product each year.
  2. Cost recovery: the disease affects more people, but there is no reasonable expectation that US sales will recover the cost of developing and making the drug. This route is rarely used because it requires detailed financial evidence.

Designation can also apply to an orphan subset of a common disease, when a property of the drug means it can only be used appropriately in that subset. A subset chosen only because it is small does not qualify.

The same drug can hold several orphan designations for different rare diseases. A drug already approved for a common disease can be designated for a new rare use.

When and how sponsors apply

A sponsor submits a request to OOPD with a description of the disease, the scientific rationale for the drug, and documentation of the US prevalence. The request must be made before the marketing application for that use is submitted. Many sponsors apply early, often around the start of human trials, because some incentives apply to work done after designation.

Designation is granted per drug and per disease. A second sponsor can seek designation for the same drug and the same disease, but must submit its own supporting data.

What orphan designation gives

IncentiveWhat it isNotes
Market exclusivity7 years from approval for the approved orphan use or indicationBlocks approval of the same drug for the same use, with exceptions
Tax credit25% of qualified clinical testing costsReduced from 50% by the 2017 tax law, starting in 2018; see the IRS rules for detail
User fee waiverExemption from the PDUFA application feeGenerally does not apply if the application also includes a non-orphan indication
GrantsFDA's Orphan Products Grants Program funds clinical studiesCompetitive, open to sponsors and researchers
Pediatric study exemptionOrphan indications are generally exempt from PREA pediatric study requirementsSince 2020, the RACE for Children Act requires pediatric studies of certain targeted cancer drugs even for orphan indications

Designation does not change the evidence standard. A drug for a rare disease is approved on the same standard of substantial evidence of effectiveness and adequate safety, though FDA can be flexible about trial design when patient numbers are small.

How orphan exclusivity works

Orphan exclusivity starts when FDA approves the drug for the designated use. For seven years, FDA generally cannot approve another application for the same drug for the same use or indication. The exceptions are:

  • The later product is shown to be clinically superior: safer, more effective, or a major contribution to patient care.
  • The holder of exclusivity cannot supply enough of the drug to meet patient needs.
  • The holder consents to the later approval.

What counts as the "same drug" depends on the product. For small molecules it is the same active moiety; for large molecules such as proteins, it turns on the principal molecular structural features. A different drug for the same disease is not blocked.

Orphan exclusivity is separate from patents and from other FDA exclusivities, such as the 5-year new chemical entity period or the 12-year reference biologic period. They can run at the same time, and whichever lasts longest controls when competitors can enter. The Orange Book vs Purple Book guide explains where patents and exclusivities are listed.

The scope question

The scope of orphan exclusivity has been litigated. In Catalyst Pharmaceuticals v. Becerra (2021), a federal appeals court read the exclusivity as covering the whole designated disease rather than only the approved use. In early 2023, FDA announced in the Federal Register that it would continue to tie exclusivity to the approved uses or indications outside that case. Congress has also considered changes. Because this area has shifted, check FDA's orphan pages for the current position.

How common orphan approvals are

Orphan drugs make up a large share of new approvals. From this site's data as of November 2026:

  • Of 48 novel drugs approved in 2026 and matched to Drugs@FDA records, 23 carry an orphan marking.
  • Original approvals with orphan marking, by year: 37 in 2019, 48 in 2020, 38 in 2021, 34 in 2022, 44 in 2023, 44 in 2024, 44 in 2025 and 28 so far in 2026.

Rare diseases treated by 2026 novel approvals include Menkes disease (Zycubo, copper histidinate, approved January 12) and spinal muscular atrophy (Isembyld, apitegromab, approved September 11). The full list is in FDA novel drug approvals in 2026.

Many orphan drugs also use an expedited program, such as breakthrough therapy or priority review. Keytruda (pembrolizumab), for example, carries an orphan marking alongside every expedited flag the site tracks. The expedited programs comparison covers how those combine.

How to find orphan drugs

FDA's orphan designation database

FDA's Orphan Drug Designations and Approvals database is the official list. You can search by drug name, disease, sponsor, or designation and approval dates. Each entry shows:

  • The generic and trade name.
  • The designated use, in FDA's wording.
  • The designation date and sponsor.
  • Whether the drug is approved for that use, with the approved indication and the exclusivity end date where applicable.

It includes designations that never led to an approval, which makes it a rough view of rare disease development, though designations are not withdrawn every time a program stops.

This site's approvals and rare disease pages

Other useful starting points:

Limits to keep in mind

  • Drugs@FDA covers CDER. Many gene and cell therapies for rare diseases are approved by CBER and will not appear in CDER-based lists.
  • An orphan marking on an approval refers to that application or indication, not to every use of the drug.
  • Requests that FDA denied are not public; the database lists only granted designations.

Frequently asked questions

What qualifies as an orphan drug?
A drug or biologic qualifies for orphan designation if it is intended for a rare disease or condition, which US law defines as affecting fewer than 200,000 people in the United States. A drug for a larger population can also qualify if there is no reasonable expectation that US sales will recover its development costs.
How long is orphan drug exclusivity?
Seven years from approval, for the approved orphan use or indication. During that time FDA generally cannot approve the same drug for the same use unless another product is shown to be clinically superior or the sponsor cannot supply enough.
Does orphan designation mean a drug is approved?
No. Designation is a status granted during development; the drug still has to go through the same approval standards of safety and effectiveness as any other drug.
Where can I find a list of orphan drugs?
FDA's Orphan Drug Designations and Approvals database lists designations and approved orphan indications, and this site's approvals tool can filter approvals marked orphan.

For information only, not medical, legal or investment advice. Facts about FDA and CMS programs are current as of the publication date; check the linked official source for changes.

Keep reading